Antitumor Effects of Lidocaine on Human Breast Cancer Cells: An In Vitro and In Vivo Experimental Trial

Chamaraux-Tran, Thiên-Nga; Mathelin, Carole; Aprahamian, Marc; Joshi, Girish P.; Tomasetto, Catherine; Diemunsch, Pierre; Akladios, Chérif

doi:10.21873/anticanres.12196

Cited by 55 publications

(52 citation statements)

References 43 publications

(68 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, growing researches have confirmed that lidocaine may perform anticancer effects on the therapy of diverse cancers through affecting tumor cell malignant behaviors, such as cell viability, apoptosis, migration and drug resistance. 4,8,21,22 In fact, sustaining proliferation and resisting apoptosis are two significant hallmarks of cancer cells that contribute to cancer cell malignant enlargement and progression, and proliferation inhibition and apoptosis promotion of cancer cells are promising methods to hinder the development of human cancers. 23 In this study, lidocaine up-regulated the proproliferative protein Cyclin D1 and pro-apoptotic proteins cleaved-Caspase-3 and cleaved-Caspase-9, which Figure 7 Lidocaine mediates CRC cell viability loss, apoptosis induction and aerobic glycolysis suppression by regulating miR-138-5p/HEY1 axis.…”

Section: Discussionmentioning

confidence: 99%

“…7 However, in addition to multiple anesthetic effects, emerging evidence has identified the antitumor effects of lidocaine in many cancers. 8 For example, lidocaine suppressed lung cancer cell proliferation by modulating the inhibition of GOLT1A. 4 Lidocaine performed anti-proliferative and apoptotic effects by regulating p53 expression in hepatocarcinoma cells to suppress tumor growth.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

<p>Lidocaine Suppresses Cell Proliferation and Aerobic Glycolysis by Regulating circHOMER1/miR-138-5p/HEY1 Axis in Colorectal Cancer</p>

Zhang

et al. 2020

CMAR

View full text Add to dashboard Cite

Background: Increasing evidence has uncovered the anticancer activity of lidocaine in many cancers. However, the role and the underlying molecular mechanism of lidocaine in colorectal cancer (CRC) remain poorly understood. Materials and Methods: Cell viability and apoptosis were measured by cell counting kit-8 assay and flow cytometry. Western blot was used to detect the protein of p53, CyclinD1, Procaspase-3, Cleaved-caspase-3, Pro-caspase-9, Cleaved-caspase-9, and hes-related family bHLH transcription factor with YRPW motif 1 (HEY1). Glycolytic metabolism was calculated by measuring the glucose consumption, lactate production and adenosine triphosphate (ATP) contents. The expression of circRNA homer scaffold protein 1 (circHOMER1), microRNA (miR)-138-5p and HEY1 mRNA was detected by quantitative real-time polymerase chain reaction. The interaction between miR-138-5p and circHOMER1 or HEY1 was analyzed using the dual-luciferase reporter assay. In vivo experiments were performed using the murine xenograft model. Results: Lidocaine suppressed CRC cell viability and aerobic glycolysis but promoted cell apoptosis in vitro as well as hindered tumor growth in vivo. CircHOMER1 was elevated in CRC tissues and cells, while lidocaine decreased circHOMER1 expression in CRC cells. Additionally, circHOMER1 overexpression reversed the anti-tumor activity of lidocaine in CRC cells. miR-138-5p was confirmed to interact with circHOMER1 and HEY1 in CRC cells directly, and circHOMER1 regulated HEY1 expression through repressing miR-138-5p expression. Besides, rescue assay indicated the anti-tumor activity mediated by lidocaine could be regulated by circHOMER1/miR-138-5p/HEY1 axis. Conclusion: Lidocaine mediated CRC cell viability loss, apoptosis induction and aerobic glycolysis inhibition by regulating circHOMER1/miR-138-5p/HEY1 axis, providing a novel treatment option for lidocaine to prevent the progression of CRC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

<p>Lidocaine Suppresses Cell Proliferation and Aerobic Glycolysis by Regulating circHOMER1/miR-138-5p/HEY1 Axis in Colorectal Cancer</p>

Zhang

et al. 2020

CMAR

View full text Add to dashboard Cite

show abstract

“…In addition, as per the safety profile, lidocaine not only shows well-tolerant toxicity ( Yang X. et al, 2018 ), selectivity in killing cancer cells over normal cells ( Chamaraux-Tran et al, 2018 ), but also may alleviate cisplatin-induced body loss in the animal studies ( Gao et al, 2018 ).…”

Section: Discussion and Future Perspectivesmentioning

confidence: 99%

“…Given lidocaine’s effect in suppressing metastasis, its further application in various breast cancer cell lines, including normal breast epithelial cells MCF-10A, luminal breast cancer cell MCF-7, TNBC MDA-MB-231, and SKBr3 human epidermal growth factor receptor 2 (HER2) positive cells and in MDA-MB-231 cells xenograft model at clinically relevant concentrations were studied ( Chamaraux-Tran et al, 2018 ). Lidocaine (0.1–10 mM determined by MTT assay) showed selectivity in suppressing the viability and migration of cancer cells over normal cells.…”

Section: Lidocaine In Cancer Treatmentmentioning

confidence: 99%

Repositioning Lidocaine as an Anticancer Drug: The Role Beyond Anesthesia

Zhou

Wang

Cui

et al. 2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

While cancer treatment has improved dramatically, it has also encountered many critical challenges, such as disease recurrence, metastasis, and drug resistance, making new drugs with novel mechanisms an urgent clinical need. The term “drug repositioning,” also known as old drugs for new uses, has emerged as one practical strategy to develop new anticancer drugs. Anesthetics have been widely used in surgical procedures to reduce the excruciating pain. Lidocaine, one of the most-used local anesthetics in clinical settings, has been found to show multi-activities, including potential in cancer treatment. Growing evidence shows that lidocaine may not only work as a chemosensitizer that sensitizes other conventional chemotherapeutics to certain resistant cancer cells, but also could suppress cancer cells growth by single use at different doses or concentrations. Lidocaine could suppress cancer cell growth in vitro and in vivo via multiple mechanisms, such as regulating epigenetic changes and promoting pro-apoptosis pathways, as well as regulating ABC transporters, metastasis, and angiogenesis, etc., providing valuable information for its further application in cancer treatment and for new drug discovery. In addition, lidocaine is now under clinical trials to treat certain types of cancer. In the current review, we summarize the research and analyze the underlying mechanisms, and address key issues in this area.

show abstract

“…In addition, lidocaine produces DNA demethylation in breast cancer cells in vitro [ 68 ]. Moreover, lidocaine, ropivacaine and bupivacaine reduce cell proliferation at concentrations of 100 μM, leading to cell cycle delay or arrest at G0/S-1 phases [ 69 ].…”

Section: Effects Of Anaesthetic Agents On Immune Function and Tumour mentioning

confidence: 99%

Anaesthesia and cancer: can anaesthetic drugs modify gene expression?

Ponferrada

Orriach

Malo-Manso

et al. 2020

ecancer

View full text Add to dashboard Cite

Cancer remains a primary cause of morbidity and mortality worldwide, and its incidence continues to increase. The most common cause of death in cancer patients is tumour recurrence. Surgery is the gold standard in the treatment of most tumours. However, cancer surgery can lead to the release of tumour cells into the systemic circulation. Surgical stress and several perioperative factors have been suggested to boost tumour growth, thereby increasing the risk of metastatic recurrence. Preclinical and clinical studies suggest that anaesthetics and adjuvants administered during the perioperative period may impact cancer recurrence and survival. This document summarises the current evidence regarding the effects of anaesthetic drugs and analgesic techniques on the immune system, systemic inflammatory response and tumour cells, as well as their impact on cancer recurrence.

show abstract

Antitumor Effects of Lidocaine on Human Breast Cancer Cells: An In Vitro and In Vivo Experimental Trial

Cited by 55 publications

References 43 publications

<p>Lidocaine Suppresses Cell Proliferation and Aerobic Glycolysis by Regulating circHOMER1/miR-138-5p/HEY1 Axis in Colorectal Cancer</p>

<p>Lidocaine Suppresses Cell Proliferation and Aerobic Glycolysis by Regulating circHOMER1/miR-138-5p/HEY1 Axis in Colorectal Cancer</p>

Repositioning Lidocaine as an Anticancer Drug: The Role Beyond Anesthesia

Anaesthesia and cancer: can anaesthetic drugs modify gene expression?

Contact Info

Product

Resources

About